Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jaguar Health Inc JAGX

Healthcare
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing... see more

Recent & Breaking News (NDAQ:JAGX)

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)

Accesswire 2 days ago

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care

Accesswire 9 days ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Accesswire 13 days ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

Accesswire April 16, 2024

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

Accesswire April 9, 2024

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Accesswire April 8, 2024

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

Accesswire April 2, 2024

Jaguar Health Reports 2023 Financial Results

Accesswire April 1, 2024

Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates

Accesswire March 27, 2024

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market

Accesswire March 20, 2024

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance

Accesswire February 23, 2024

Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Accesswire February 15, 2024

Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief

Accesswire February 14, 2024

Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea

Accesswire February 12, 2024

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions

Accesswire January 30, 2024

Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference

Accesswire January 29, 2024

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)

Accesswire January 25, 2024

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accesswire January 5, 2024

Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

Accesswire January 4, 2024

A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II

Accesswire December 11, 2023